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A B S T R A C T
The lack of Croatian studies which could determine the justifiability of excessive psychopharmaceutical utilization
was an encouragement to conduct this research. Furthermore, regarding the conduction of this study, it would be possi-
ble to determine whether the trend of drug utilization has increased, decreased or perhaps stabilized. The data on the
outpatient utilization of psycholeptics and psychoanaleptics were collected from all Zagreb pharmacies, 2006–2009. Ba-
sed on the collected data for all N05 and N06 groups of drugs, the defined daily doses (DDD) and DDD per thousand in-
habitants per day (DDD/TID) have been calculated using the Anatomical-Therapeutic-Chemical classification (ATC) for
2006, 2007, 2008 and 2009. To indicate the quality of drug prescription the Drug Utilization 90% (DU 90%) method was
used. Moreover, in order to determine a more precise quality of individual drug group prescriptions, the indicators have
been calculated by determining the proportion of the total utilization of individual therapeutic and pharmacological
therapeutic subgroups in DDD/TID a day. The utilization of anxiolytics (N05B) accounts for most of the psycholeptic uti-
lization in the City of Zagreb throughout the entire study period. In the study period, the utilization of antidepressants
has slightly increased, by 10.5%, taking the first and the last years of the period into account. In 2006, 5 benzodiazepines
and the hypnotic zolpidem, as well as 5 selective serotonin reuptake inhibitors (SSRIs) and 1 third generation antipsy-
chotic (olanzapin) were found in the DU 90% segment. In 2009, the DU 90% segment also comprised 5 benzodiazepines
and the hypnotic zolpidem, as well as 6 SSRIs and 1 third generation antipsychotic (olanzapin). In the City of Zagreb, a
general insight into the quality of psychopharmaceutical prescriptions indicates stability in comparison to earlier stud-
ies. The ratio index of the first generation antipsychotic utilization, compared to the third generation antipsychotics,
shows an increase in the quality of prescription. Also, the ratio index of total tricyclic antidepressants (TCA) and SSRI
utilization indicates improvement in quality of prescription. The ratio index of the entire outpatient utilization of anxio-
lytics and antidepressants expressed in DDD/TID unfortunately shows a very mild increase of prescription quality. Ben-
zodiazepines accounted for more than 50% of the outpatient utilization of psychopharmaceuticals throughout the study
period, which proves the need for precise guidelines as the most significant means of drug rationalization and utiliza-
tion. It is necessary to identify priorities and problems in order to solve them successfully, by monitoring drug utilization
and prescription on a national level. Results demonstrate that within the primary health care system, there is a need for
constant education on rational prescription of this drug group.
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Introduction
Zagreb accounts for the 18% of Croatian population
and 43% of Croatian health resources, so that the city ac-
curately represents Croatian trends, with the quality of
drug prescription most likely being the same or smal-
ler1,2. Nowadays, drug utilization is the main focus of nu-
merous political, economical and medical debates in a
large number of countries. Even in the most developed
countries, increase in drug utilization is virtually impos-
sible to determine by estimating an increase in the gross
domestic product (GDP). Insight into drug utilization, as
an economical and primarily a public health issue, can be
acquired only within the context of the overall health
state of the respective population. A reform of the drug
prescription system is a part of an overall health care re-
form that is currently being conducted in the Republic of
Croatia3. Outpatient utilization and the utilization of
psycho pharmaceuticals are further significant elements
of drug utilization within a certain society. As this drug
group affects the nervous system, the basis of the afore-
mentioned reform should be the establishment of uni-
form national guidelines for psychopharmaceutical pre-
scription. According to the Intercontinental Marketing
Service (IMS) data, the leading group of drugs consumed
in the world are cardio-vascular drugs, followed by cen-
tral nervous system drugs (CNS), with a constant annual
increase of 11%4. The ageing of the population, the emer-
gence of new drugs in the market as well as the impact of
pharmaceutical industry marketing are just some of the
reasons for a continuous increase in drug utilization5,6. A
similar pattern has been recorded in Croatia, with the
predominance of cardio-vascular drug utilization, fol-
lowed by the CNS drug utilization7,8. The issue of psycho-
pharmaceutical utilization has been detected even in the
most developed countries, such as the USA9. The lack of
Croatian studies determining possible justifications for
such excessive psychopharmaceutical utilization has en-
couraged us to carry out this research. So far, only one
study has demonstrated improvement in the quality of
psycho pharmaceutical utilization, but with an excessive
utilization of benzodiazepines, thus indicating need for
rationalization3. Also, with regards to the aforemen-
tioned study, it is possible to determine whether the utili-
zation trend has increased, decreased or stagnated.
Research Objectives
Research objectives were as follows:
1) to determine the real outpatient utilization of psy-
chopharmaceuticals in the City of Zagreb, the capital of
Croatia, using the Anatomical-Therapeutic-Chemical
drug classification (ATC) and the defined daily doses unit
(DDD)10–12,
2) to determine the quality of outpatient psycho-
pharmaceutical prescription during the study period by
using indexes calculated from the ratio of certain sub-
groups of the N group and by means of the Drug Utiliza-
tion 90% (DU 90%) methodology13, and
3) to propose appropriate interventions in the City of
Zagreb and perhaps in the whole of Croatia on the basis
of results so achieved.
Methods
Data on the outpatient utilization of psycholeptics
and psychoanaleptics (ATC group N05 and N06) in the
City of Zagreb, were collected between 2006 and 2009.
They were acquired from Zagreb’s pharmacies that had
recorded the data based on individual reedmed prescrip-
tions, which are sent routinely in an electronical form to
»Dr. Andrija [tampar« Institute of Public Health. All the
drugs have been classified according to the ATC system.
The data acquired have been used to calculate the DDD
and the DDD per thousand inhabitants per day (DDD/
TID), by using the indexes of: 2006, 2007, 2008 and
200914–17. DDD unit is defined as the assumed average
maintenance dose per day for a drug or drug group when
used for its main indication in adults. ATC/DDDmethod-
ology is recognized formally as an international standard
system for drug utilization studies by WHO Collabo-
rating Centre for Drug Statistics Methodology. The DDD/
TID calculations were based on the census of 2001, ac-
cording to which the population of Zagreb was 770 588.
Prescription data presented in DDDs per 1000 inhabit-
ants per day provide an estimate of the proportion of the
study population treated daily with a particular drug or
group of drugs, particularly useful for international com-
parisons of drug utilization. The DU 90% method was
used to determine the quality, or in other words, adher-
ence of psycho pharmaceutical prescription to current
guidelines13,18. The DU90% method adds to qualitative
aspects of the ATC – DDD methodology, also confirmed
and recognized by WHO.
Also, in order to determine, in a more detailed man-
ner, the prescription quality of certain drug groups, indi-
cators have been calculated using the ratio of the overall
utilization of certain therapeutic and pharmacothera-
peutic subgroups in DDD/TID. The focus was on the ra-
tio of anxiolytics and antidepressants (groups N05B and
N06A) to determine the correlation of their utilization
and the tendency of their individual prescriptions, which
additionally depicts the overall quality of drug prescrip-
tion. The indicator has been obtained from the ratio of
the general N05B and N06A group utilization expressed
in DDD/TID. Furthermore, the same process was used to
compare tricyclic antidepressants (TCA) to selective se-
rotonin reuptake inhibitors (SSRI) by calculating the ra-
tio of total utilization of these pharmacotherapeutic sub-
groups in DDD/TID, in order to establish the pattern of
antidepressant subgroups prescription and the degree to
which it adheres to the latest therapeutic possibilities,
which once again indicates the quality and effectiveness
of recommendation monitoring. The indicator was, as
previously, calculated by using the ratio of the total utili-
zation in DDD/TID regarding both first and third gener-
ations of antipsychotics. A unique indicator was calcu-
lated for each year of the study period from 2006 until
2009, in addition to monitoring the indicators’ alter-
ations in time.
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Results
According to the ATC classification, psychopharma-
ceuticals are divided into two main groups: psycholeptics
(N05) which include antipsychotics (N05A), anxiolytics
(N05B) and hypnotics (N05C); and psychoanaleptics
(N06), including antidepressants (N06A). The remaining
N06 subgroups have not been taken into account due to
their minor share in utilization.
Table 1 demonstrates the outpatient utilization of
psycholeptics and psychoanaleptics. Between 2006 and
2009, the total utilization had a growing tendency, reach-
ing its peak in year 2008, after which it is slightly de-
creased in the last year of this period. The anxiolytic
(N05B) utilization accounts for most of the psycholeptic
utilization in the City of Zagreb throughout the entire
study period. The utilization of antidepressants (N06A)
accounts for almost all psychoanaleptic utilization, not
less than 97%, so that the aforementioned drug group
was the only one considered. There was a slight increase,
by 10.5%, in the utilization of antidepressants within the
study period, including the years 2006 and 2009. The an-
tidepressant utilization reached its peak in 2008, having
increased by 9% since 2007 and 15.5% since 2006. Figure
1 demonstrates the quality indicators of outpatient pre-
scription of anxiolytics and antidepressants. The quality
indicators have been derived from the ratio of the entire
anxiolytic and antidepressant utilization expressed in
DDD/TID for each year of the study period. The index
clearly demonstrates that the utilization of anxiolytics is
2 to 3 times larger than antidepressant utilization. Fig-
ure 1 graphically depicts the decrease in the index value,
which indicates an increase in the share of the antide-
pressant utilization. Figure 2 demonstrates the prescrip-
tion quality indicators of the outpatient utilization of
tricyclic antidepressants and selective serotonin reup-
take inhibitors. The quality indicators have been derived
from the ratio of the total TCA and SSRI utilization in
DDD/TID for each year of the study period. The index re-
veals that the TCA utilization is 10 times lower than the
SSRI utilization. Furthermore, Figure 2 graphically de-
picts decrease in the index value, which indicates incre-
ase in the share of the SSRI utilization. Figure 3 depicts
the prescription quality indicators of the outpatient utili-
zation of the first and third generations of antipsy-
chotics. The quality indicators have been derived from
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TABLE 1
OUTPATIENT UTILIZATION OF PSYCHOLEPTICS (N05) AND PSYCHOANALEPTICS (N06) IN THE CITY OF ZAGREB,
FROM 2006 TO 2009, EXPRESSED IN THE DDD/TID UNIT
ATC code 2006 2007 2008 2009
N05A 8.26 8.70 8.78 8.6
N05B 53.44 54.42 57.44 52.16
N05C 12.82 14.41 15.78 15.34
N05 74.52 77.53 82.00 76.10
N06(N06A) 18.65 20.24 22.06 20.82
Total N05, N06 93.17 97.77 104.06 96.92
Legend: ATC – Anatomical-Therapeutic-Chemical classification, N05A – Antipsychotics, N05B – Anxiolytics, N05C – Hypnotics and
sedatives, N06A – Antidepressants
Fig. 1. Quality trend of the outpatient anxiolytic and antidepres-
sant prescription in the City of Zagreb 2006–2009, expressed in
the DDD/TID ratio of the total anxiolytic anantidepressant utili-
zation.
Fig. 2. Quality trend of the outpatient prescription of tricyclic an-
tidepressants (TCA) and selective serotonin reuptake inhibitors
(SSRI) in the City of Zagreb 2006–2009, expressed in the DDD/
TID ratio of the total TCA and SSRI utilization.
Fig. 3. Quality trend of the outpatient prescription of the first
and third generation antipsychotics in the City of Zagreb 2006–
2009, expressed in the DDD/TID ratio of the total utilization of
the first and third generation antipsychotics.
the ratio of the total utilization of the first and third gen-
erations of anti-psychotics in DDD/TID for each year of
the study period. The index demonstrates the utilization
of the first generation antipsychotic being larger than
the utilization of the third generation antipsychotics.
Figure 3 also graphically depicts the decrease in the in-
dex value, which indicates an increase in the share of the
third generation antipsychotic utilization. In 2006, the
DU 90% segment included 5 benzodiazepines and the
hypnotic zolpidem, 5 SSRIs and a third generation anti-
psychotic (olanzapine). Furthermore, in 2009, the DU
90% segment also included 5 benzodiazepines and the
hypnotic zolpidem, 6 SSRIs and a third generation anti-
psychotic (olanzapine).
Benzodiazepines account for the most of outpatient
psychopharmaceutical utilization, their utilization rea-
ching its peak in 2008, after which it was reduced to its
previous state in 2009. The diazepam utilization in-
creased during the study period and reached its peak in
2008, so it is currently leading at the market. Zolpidem’s
increase is continuous, whereas the utilization of alpra-
zolam is stable and that of oxazepam has slightly de-
creased (Figure 4). Compared to antidepressants, anxio-
lytics demonstrate twice the rate of utilization expressed
in DDD/TID, as shown in Figure 5. The SSRI utilization
is 8 to 9 times larger than the TCA utilization, as shown
in Figure 6. Out of all SSRI antidepressants, sertraline
has the largest utilization, which continuously increased
and reached its peak in 2008. The utilization of paroxe-
tine directly follows that of sertraline. It was relatively
constant until 2009, when it slightly decreased. Fluvoxa-
mine demonstrates an increase in utilization, while the
utilization of escitalopram shows no significant changes
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Fig. 4. Outpatient utilization of benzodiazepine from the Drug
Utilization 90% (DU90%) segment and the hypnotic zolpidem,
expressed in DDD/TID, in the City of Zagreb from 2006 to 2009.
Legend: DDD/TID – defined daily doses per thousand inhabit-
ants per day.
Fig. 5. The comparison between the total outpatient utilization of
antidepressants and anxiolytics in the City of Zagreb between
2006 and 2009, expressed in DDD/TID. Legend: DDD/TID – de-
fined daily doses per thousand inhabitants per day.
TABLE 2
PSYCHOLEPTICS AND PSYCHOANALEPTICS INCLUDED IN THE DRUG UTILIZATION 90% (DU 90%) SEGMENT, EXPRESSED IN THE
DDD UNITS, AND THE TOTAL AMOUNT OF DRUGS OUTSIDE OF THE DU 90% SEGMENT, IN THE CITY OF ZAGREB IN 2006
Number Drug name DDD Share (%) DDD/TID
1. Diazepam 1.490.169 22.4 21.0
2. Alprazolam 1.019.355 15.3 14.3
3. Oxazepam 839.934 12.6 11.8
4. Zolpidem 662.540 10.0 9.3
5. Lorazepam 449.032 6.7 6.3
6. Paroxetine 323.145 4.9 4.6
7. Sertraline 292.124 4.4 4.1
8. Fluoxetine 194.992 2.9 2.7
9. Nitrazepam 188.640 2.8 2.7
10. Escitalopram 188.300 2.8 2.7
11. Olanzapine 170.814 2.6 2.4
12. Fluvoxamine 103.920 1.6 1.5
DU90% 1–12 5.922.965 89.4 83.3
Remaining 12–36 739.054 10.6 9.9
Total 1–36 6.662.019 100.0 93.2
Legend: DDD – defined daily doses, DDD/TID – defined daily doses per thousand inhabitants per day
during the study period (Figure 6). Olanzapine, a third
generation antipsychotic of the DU 90%, accounts for
one fourth of the entire antipsychotic utilization. The
trend of the overall utilization as well as the utilization of
olanzapine in the study period was stable, having slightly
increased in 2008 (Figure 7, Tables 2 and 3).
Discussion
Regarding the entire outpatient utilization in the City
of Zagreb, a group of drugs affecting the nervous system
(ATC group N) takes second place. Psychopharmaceu-
ticals account for 70% of the group N’s utilization and 9
to 10% of the overall drug utilization19. High psycho-
pharmaceutical utilization in the City of Zagreb is sup-
ported by morbidity indicators. A group of mental and
behavioral disorders takes the fifth place regarding hos-
pital morbidity and hospitalization and also accounts for
7.4% of all morbidity and hospitalizations. The group of
mental and behavioral disorders represented a signifi-
cant share of diagnosed health issues within the primary
health care system, exactly 5.2%, as well as 3.5% of all di-
agnosed conditions in emergency rooms20. The group of
mental disorders (F00–F99) was the seventh most com-
mon hospitalization cause in Croatia in 2007, accounting
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Fig. 7. Outpatient antipsychotic utilization in the City of Zagreb,
with the utilization share of olanzapine, expressed in DDD/TID
between 2006 and 2009. Legend: DDD/TID – defined daily doses
per thousand inhabitants per day.
TABLE 3
PSYCHOLEPTICS AND PSYCHOANALEPTICS INCLUDED IN THE DRUG UTILIZATION 90% (DU 90%) SEGMENT, EXPRESSED IN THE
DDD UNITS, AND THE TOTAL AMOUNT OF DRUGS OUTSIDE OF THE DU 90% SEGMENT, IN THE CITY OF ZAGREB IN 2009
Number Drug name DDD Share (%) DDD/TID
1. Diazepam 1.685.685 24.5 23.71
2. Alprazolam 1.075.005 15.6 15.12
3. Zolpidem 870.240 12.6 12.24
4. Oxazepam 554.655 8.1 7.80
5. Lorazepam 393.580 5.7 5.54
6. Sertraline 353.662 5.1 4.97
7. Paroxetine 286.950 4.2 4.04
8. Olanzapine 190.470 2.8 2.68
9. Escitalopram 170.324 2.4 2.40
10. Nitrazepam 161.580 2.3 2.27
11. Citalopram 158.084 2.3 2.22
12. Fluvoxamine 142.080 2.1 2.00
13. Fluoxetine 130.984 1.9 1.84
DU90% 1–13 6.173.299 89.6 86.83
Remaining 13–37 718.340 10.4 10.10
Total 1–37 6.891.639 100.0 96.93
Legend: DDD – defined daily doses, DDD/TID – defined daily doses per thousand inhabitants per day
Fig. 6. Outpatient utilization of tricyclic antidepressants (TCA),
the total utilization of the selective serotonin reuptake inhibitors
(SSRI) and the utilization of most important individual SSRI
drugs in the City of Zagreb between 2006. and 2009, expressed in
DDD/TID. Legend: DDD/TID – defined daily doses per thousand
inhabitants per day.
for 7.2% of all hospitalizations. According to the length of
hospital treatment expressed in days, in Croatia mental
disorders and illnesses occupy the first place accounting
for 21.7% of all days of hospital treatment in general. In
2007, every fifth day of hospital treatment (1 474 305 bed
days) was spent on treating mental disorders. As of 2007,
almost two thirds of all hospitalization causes included
the following four diagnostic groups: alcohol-related
mental disorders (20.6%), schizophrenia (15.7%), severe
stress reactions, including posttraumatic stress disorder
(PTSD) (13.6%) and depressive disorders (11.7%). Be-
tween 1995 and 2007, there was a constant increase in
the number and rate of hospitalizations caused by men-
tal disorders. The rate of such hospitalization equaled
632.2/100 000 in 1995, while in 2007, it amounted to
1039.0/100 000. Mental illnesses were rarely found to be
causes of death. In 2007, they took 8th place of all mortal-
ity causes in Croatia, with a 1.5% rate 21.
The group of psycholeptics accounts for two thirds of
the entire N group utilization and for years, it has been
one of the most prescribed drug groups19. The antipsy-
chotic utilization shows a stable trend within the study
period, with a slight increase in 2008 and a decrease in
2009. The average of the first generation antipsychotic
utilization throughout the study period equals 2.86
DDD/TID, whereas the average of the third generation
antipsychotic utilization equals 4.3 DDD/TID. The index
of the first generation antipsychotic utilization compared
to the third generation antipsychotics was 0.73, in 2006,
and 0.63 in 2009. This indicates a constant improvement
in the quality of antipsychotic prescription, as the third
generation antipsychotics are a result of a targeted
search for the best possible antipsychotic with as few
side-effects as possible. Atypical antipsychotics are con-
sidered to be the first choice of therapy for patients with
psychotic disorders and are preferred over first genera-
tion antipsychotics22. The development of a personalized
psychopharmacotherapy for schizophrenia depends on
the availability of a sufficient number of modern anti-
psychotics that should be the first choice of treatment for
this degenerative mental illness23. According to some re-
cent findings, current antipsychotics have been accepted
in the City of Zagreb24, as shown in the results. Although
the current antipsychotics are effective having far less
side-effects, pharmacoeconomic analyses demonstrate
inconsistencies regarding the profitability of their high
prices25–28. According to recent studies and this research,
the utilization of olanzapine is highest among the third
generation antipsychotics, although, due to its price; the
Croatian Institute of Health Insurance (HZZO) has re-
stricted the prescription of this agent exclusively to cases
resistant or intolerant to classical therapies29. It can be
said that the prescription quality satisfies the general
guidelines for tolerability and effectiveness of antipsy-
chotics, whereas from a pharmacoeconomical perspec-
tive, steps towards improvement are yet to be taken.
The benzodiazepine utilization equals 68.09 DDD/
TID on average throughout the study period, reaching its
peak in 2008 with 72.29 DDD/TID. Diazepam accounts
for most of this group’s utilization, its utilization show-
ing a constant increase within the study period.
Zolpidem, a partial non-benzodiazepine agonist of benzo-
diazepine receptors that reduces the stage of falling
asleep and prolongs the overall sleep time, is recom-
mended as the first choice for insomnia treatment among
standard treatments30. Throughout the study period,
zolpidem shows a slight increase, smaller than the in-
crease of diazepam. Alprazolam and oxazepam demon-
strate a decrease in utilization within the study period,
which is in case of oxazepam due to it no longer being
prescribed free of charge since 2006. The relative un-
availability of oxazepam might be the reason behind a
partial increase in the utilization of diazepam. Taking
into account the possible side-effects of non-critical
benzodiazepine use, their utilization in Zagreb is ex-
tremely high and inappropriate. The outpatient utiliza-
tion of benzodiazepines, particularly diazepam, is much
higher in Croatia than, for instance, in Scandinavian
countries, which is evident from the DDD/TID number
and the share of the DU 90% segment31.
The average antidepressant utilization in the study
period amounts to 20.42 DDD/TID. The TCA utilization
is 1.47 DDD/TID averagely, whereas for SSRI, it equals
17.4 DDD/TID. There is a certain increase in the total
antidepressant utilization which reaches its peak in
2008. The ratio index of the total TCA and SSRI utiliza-
tion equaled 0.103 in 2006, having decreased to 0.075 in
2009. This signifies an existing quality of the antidepres-
sant prescription as well as a particular tendency to-
wards continuous quality improvement. SSRIs are con-
sidered to be the first choice of therapy for depressive
disorders, being designated by a smaller intrinsic toxicity
and better tolerability, so that all doctors in the primary
health care system can and should prescribe them. Tri-
cyclic antidepressants are the second choice drugs and
should be prescribed only under strict psychiatric super-
vision22. The results demonstrate noticeable adherence
to current information and prescription trends. Sertaline
accounts for the most of SSRI utilization, showing an in-
crease in utilization within the study period. It amounted
to 4.1 DDD/TID in 2006, only to reach 4.97 DDD/TID in
2009. Sertraline is a selective serotonin reuptake inhibi-
tor used and extensively studied in the world. It was
proven safe and very tolerable. Randomized clinical stud-
ies have found it to be an effective treatment for depres-
sion and anxious disorders, and its efficiency has re-
mained unchanged by psychiatric comorbidity. In non-
-comorbid patients, sertraline is an effective treatment
for acute severe depressive disorders and chronic anxious
disorders. It has also been proven effective in treating
acute and chronic anxious disorders, posttraumatic
stress disorders, panic disorders and generalized anxious
disorder32. The utilization of paroxetine directly follows
that of sertraline, although it shows decrease in the last
two years of the study period. In 2006, its utilization
equaled 4.6. DDD/TID, whereas in 2009, amounted to
4.04 DDD/TID. It has similar side-effects as sertraline
and, accordingly, the difference in prescription within
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the study period is not significant. Escitalopram and
fluvoxamine account for a small part of the SSRI utiliza-
tion and show a trend remaining stable throughout the
whole study period. According to several studies, esci-
talopram is the most selective of all SSRIs. This indicates
that its prescriptions could be even more frequent33.
Also, certain studies confirm that the cost/benefit of
escitalopram justifies focus of this study on that very
agent34.
The ratio index of the entire outpatient utilization of
anxiolytics and antidepressants expressed in DDD/TID
equals 2.66 on average, being 2.86 in 2006 and 2.5 in
2009. Despite this slight increase in the utilization of an-
tidepressants as an ethiological therapy, in contrast to
anxiolytics which are a symptomatic therapy, there was
no significant variations in the study period, particularly
compared to previous data3. The aforementioned facts
indicate that there is room for improvement in the qual-
ity of anxiolytic and antidepressant prescription.
The DU 90% segment from 2006 and 2009 does not
show a significant difference indicating a lack of consid-
erable dynamic in drug prescription. This is positive,
considering the prescription adherence to newer drugs.
For instance, no less than 5 SSRIs belonged to the DU
90% segment in 2006 and six of them were in the seg-
ment in 2009. Regarding the aforementioned arguments
about aspects of these drugs, their effectiveness, side-ef-
fects being fewer and their profitability, the antidepres-
sant prescription looks promising. Diazepam holds the
first place in the DU 90% segment in both studied years,
which has already been characterized as an excessive uti-
lization due to the drug characteristics and a comparison
with developed countries. On the other hand, zolpidem, a
standard treatment for insomnia, took fourth place in
2006 and reached a high third place in 2009. This indi-
cates the adherence to guidelines in standard insomnia
treatments. However, its utilization is overly excessive,
seeing that it is only a symptomatic therapy and not etio-
logical. The only antipsychotic in the DU 90% segment is
olanzapine, a third generation antipsychotic, as a reflec-
tion of improved quality in antipsychotic prescription. In
2006, five benzidoazepines and zolpidem belonged to the
DU 90% segment and the same pattern repeats in 2009.
Taking into consideration the side-effects that can be
triggered by a non-critical utilization, from tolerability to
development of addiction, efforts should be made to-
wards the reduction of excessive prescription. The ratio-
nalization measurements have been proven ineffective in
the reduction of benzodiazepine prescription and should
therefore be significantly and zealously improved. The
utilization of psychotropic drugs is not only a medical
problem but also a complex social issue. Doctors must
prescribe these drugs within strict limits and based on
the most rigorous medical indications, so that their pre-
scription indeed matches the accurate diagnosis, and
carefully use certain pharmacotherapeutic substances,
bearing possible side-effects in mind, especially those re-
lated to inappropriate utilization or misuse35.
Conclusion
According to the results presented in this study the
following was concluded: 1) During the observed time pe-
riod the total utilization of psycholeptics and psychoana-
leptics had the tendency of growth, 2) Anxiolytics ac-
count for most of psycholeptic group utilization, 3) Uti-
lization of benzodiazepines in Zagreb is extremely high
and inappropriate, 4) Antidepressants account for the
majority of psychoanaleptic drug utilization, 5) Prescrip-
tion of antidepressants shows a tendency towards a con-
tinuous quality improvement, 6) There is a constant im-
provement in the quality of antipsychotic prescription, 7)
There is adherence to guidelines in standard insomnia
treatments, 8) There is still extent for improvement in
the quality of anxiolytic and antidepressant prescription.
A general insight into the quality of psychopharma-
ceutical utilization in the City of Zagreb indicates a sta-
ble trend in contrast to recent studies. In the study pe-
riod, benzodiazepines recurrently accounted for more
than 50% of outpatient psychopharmaceutical utiliza-
tion. This confirms a need for clear guidelines as the
most important rationalization measurement in pres-
cription and utilization. In addition, it is necessary to
identify priorities and problems in order to successfully
solve them, by monitoring drug utilization and prescrip-
tion on a national level. The results demonstrate that
within the primary health care system, there is a need
for constant education on rationally prescribing this
drug group. The general population should be informed
about possible side-effects of psychopharmaceuticals,
and the cooperation of patients should be constantly
monitored.
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ISTRA@IVANJE KVALITETE IZVANBOLNI^KOG PROPISIVANJA PSIHOFARMAKA
U GRADU ZAGREBU 2006.–2009. GODINE
S A @ E T A K
Manjak studija u Hrvatskoj koje bi utvrdile opravdanost prevelike potro{nje psihofarmaka bio je poticaj da se prove-
de ovo istra`ivanje. Obzirom na provedbu navedene studije bilo bi mogu}e utvrditi je li do{lo do pove}anja, smanjenja ili
stabilizacije trendova. Podaci o izvanbolni~koj potro{nji psiholeptika i psihoanaleptika prikupljani su u razdoblju od
2006.–2009. godine iz svih ljekarni Grada Zagreba. Na temelju prikupljenih podataka su za sve lijekove N05 i N06
grupa izra~unate definirane dnevne doze (DDD) i DDD/1000 stanovnika/dan, koriste}i anatomsko-terapijsko-kemijsku
klasifikaciju (ATK) za 2006., 2007., 2008. i 2009. godinu. Za kvalitetu propisivanja, kori{tena je DU 90% metoda (Drug
Utilization 90%). Tako|er, da bi se suptilnije utvrdila kvaliteta propisivanja pojedinih skupina lijekova, izra~unati su
indikatori kroz omjere ukupne potro{nje pojedinih terapijskih i farmakolo{ko-terapijskih podskupina u DDD/1000 sta-
novnika/dan. Potro{nja anksiolitika (N05B) ~ini ve}inu potro{nje psiholeptika u Gradu Zagrebu, kroz cijelo promatrano
razdoblje. Tijekom razdoblja istra`ivanja do{lo je do blagog porasta potro{nje antidepresiva, za 10,5% uzimaju}i u obzir
prvu i zadnju godinu istra`ivanog perioda. U 2006. godini 5 benzodiazepina i hipnotik zolpidem, 5 SSRI i jedan antipsi-
hotik tre}e generacije (olanzapin) se nalaze u DU 90% segmentu. U 2009. godini se u DU 90% segmentu nalazi tako|er
5 benzodiazepina i hipnotik zolpidem, 6 SSRI i jedan antipsihotik tre}e generacije (olanzapin) se nalaze u DU 90%
segmentu. Op}i uvid u kvalitetu propisivanja psihofarmaka u Gradu Zagrebu ukazuje na stabilan trend u odnosu na
ranije studije. Indeks omjera propisivanja antipsihotika prve i tre}e generacije pokazao je pobolj{anje u kvaliteti pro-
pisivanja. Tako|er, indeks TCA i SSRI pokazuje pobolj{anje kvalitete propisivanja antidepresiva u promatranom raz-
doblju. Nadalje, indeks omjera propisivanja anksiolitika i antidepresiva pokazao je slabo pobolj{anje kvalitete u propisi-
vanju etiolo{ke terapije. Benzodiazepini tijekom istra`ivanog razdoblja ~inili su redovito vi{e od 50% izvanbolni~ke
potro{nje psihofarmaka, {to potvr|uje potrebu za jasnim smjernicama kao najbitnijom mjerom racionalizacije u potro{-
nji i propisivanju. Nu`no je pra}enje potro{nje i propisivanja lijekova na nacionalnoj razini. Rezultati pokazuju da na
razini primarne zdravstvene za{tite postoji potreba za trajnom edukacijom racionalnog propisivanja lijekova iz ove
grupe.
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